Allergan may be facing investor pressure to sell off some businesses—and to get its share price back on an upward trajectory—but the company managed to beat Street estimates with its first-quarter earnings. And that’s despite generic competition for some of
read moreThat was remarkably fast: Just nine days into its Gardasil 9 review, China’s revamped drug regulator handed Merck’s HPV vaccine a conditional green light—a new approval tool the agency is testing in its quest to speed new drugs to market.
read moreUS regulators are undertaking a priority review of Sanofi and Regeneron’s cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC), or those with locally advanced CSCC who are not candidates for surgery. More: US priority review
read moreEuropean regulatory advisors are supporting approval of AstraZeneca’s lung cancer drug Tagrisso in the first-line setting. More: AZ’ lung cancer drug Tagrisso backed for first-line use Source: News
read moreThree medicines treating HIV, pain and cancer have been recommended for approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) at its latest meeting. More: Three medicines step closer to EU approval Source: News
read moreMSD’s Keytruda has become the only immunotherapy to be funded by the NHS for the treatment of bladder cancer, following a final green light from cost regulators. More: Final NICE nod for Keytruda in bladder cancer Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals